Naveen Bellam, MD
Advanced Heart Failure and Transplant Cardiology · Orlando, FLNPI 1619260239
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $321,986 of the $413,923 with a category attached, or 77.8%. Alnylam Pharmaceuticals Inc. accounts for 60.4% of it on its own, with 30 other manufacturers making up the rest. Among advanced heart failure and transplant cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 580 payments — averaging $713.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$250K
- Merck$99K
- Bridgebio Pharma, Inc.$31K
- Impulse Dynamics (USA) Inc.$19K
- Pfizer$11K
- Abbott$1K
- plus $3K from 25 others
What the payments were for
- Consulting fees$14,7754%
- Speaking & faculty fees$321,98678%
- Travel & lodging$60,59515%
- Food & beverage$16,5324%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 315 | $250,124 |
| Merck | 81 | $99,423 |
| Bridgebio Pharma, Inc. | 35 | $30,637 |
| Impulse Dynamics (USA) Inc. | 41 | $18,531 |
| Pfizer | 19 | $10,949 |
| Abbott | 29 | $1,219 |
| Cvrx, Inc. | 21 | $840 |
| Medtronic | 2 | $219 |
| Kestra Medical Technology Services, Inc. | 3 | $201 |
| Abiomed | 2 | $176 |
| Boston Scientific | 1 | $147 |
| Daxor Corporation | 2 | $145 |
| Akcea Therapeutics, Inc. | 1 | $138 |
| United Therapeutics Corporation | 1 | $134 |
| Nuwellis, Inc. | 1 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| Novo Nordisk | 1 | $111 |
| Boehringer Ingelheim | 2 | $103 |
| American Regent | 2 | $98 |
| E.r. Squibb & Sons, L.L.C. | 5 | $96 |
| AstraZeneca | 1 | $53 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $52 |
| Cardiac Dimensions, Inc. | 2 | $52 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Eurofins Viracor, LLC | 1 | $37 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $30 |
| Sanofi | 1 | $29 |
| Bayer | 1 | $27 |
| Briohealth Solutions, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$175,948
- AMVUTTRA$168,441
- ONPATTRO$76,137
- OPTIMIZER$35,954
- Attruby$30,276
- VYNDAQEL$4,825
- VYNDAMAX$2,721
- Barostim Neo System$329
- HeartMate$272
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$258
- HeartWare HVAD$219
- WATCHMAN Access System$147
- TEGSEDI$138
- Assure WCD$136
- REMODULIN$134
- TYVASO$134
- NONE$134
- AQUADEX SMARTFLOW CONSOLE$128
- LIVTENCITY$122
- BVA-100$120
How this compares
$413,923 in reported general payments places this provider in the 95th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 38 | $1,122,022 |
| EntrestoSacubitril/Valsartan | 36 | $47,443 |
| JardianceEmpagliflozin | 34 | $38,066 |
| VerquvoVericiguat | 15 | $16,611 |
| Tacrolimus | 143 | $16,593 |
| Mycophenolate Mofetil | 124 | $12,548 |
| FarxigaDapagliflozin Propanediol | 19 | $11,196 |
| EliquisApixaban | 12 | $7,435 |
| Sirolimus | 11 | $3,327 |
| Pravastatin Sodium | 82 | $921 |
| Metoprolol Succinate | 37 | $701 |
| Bumetanide | 20 | $562 |
| Torsemide | 17 | $516 |
| Spironolactone | 79 | $489 |
| Rosuvastatin Calcium | 68 | $476 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $10,949 | $1,129,45750 claims |
| Boehringer IngelheimJardiance | $103 | $38,06634 claims |
| MerckVerquvo | $99,423 | $16,61115 claims |
| AstraZenecaFarxiga | $53 | $11,19619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Orlando
- Stacy MandrasOrlando$100K
- Pujan PatelOrlando$66K
- Andrija VidicOrlando$18K
- Shahid QamarOrlando$9K
- Jacqueline DoweOrlando$7K
- Sushma KoneruOrlando$7K
- Mauricio VelezOrlando$6K
- Akanksha AgrawalOrlando$5K
- Krithika KrishnaraoOrlando$4K
- Maria DemoriOrlando$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.